Home Psoriasis Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for...

Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for Development as a Novel Cancer Therapeutic

70
0

 

NEW YORK, Oct. 20, 2020 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that through its commercial licensing agreement with the University of Maryland, Baltimore (UMB) the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 10,793,525 related to novel 13-Cis-RAMBA retinamides optimized to target key signaling pathways implicated in a variety of cancers.  This patent is also the first of its kind, expiring on October 5, 2036.


(PRNewsfoto/Hoth Therapeutics Inc.)


Numerous cancer types, including breast, prostate, bladder, and pancreatic cancers, share a similar oncogenic lineage through hyperactivation of a biochemical signaling cascade that promotes cancer initiation, progression, and metastases. This cancerous signal “hijacking” is controlled by two proteins, MAPK-interacting kinases 1 and 2 (or MNK 1/2); therefore, restoring control of the signaling pathway promotes programmed cell death (apoptosis) and inhibits cell growth. Researchers at UMB discovered novel 13-cis-retinoic acid metabolism blocking agent (RAMBAs) retinamides that are targeted to interrupt the MNK1/2-driven signaling pathway as potential therapeutics for various cancers. The potential therapeutic utility of these novel RAMBAs was shown in tumor xenograft animal models for both breast and prostate cancer. 


Last year, Hoth Therapeutics announced that it had entered into a Commercial Licensing Agreement with University of Maryland, Baltimore for the development of  HT-003, a related but chemically different RAMBA, being developed for the treatment of acne and psoriasis. 


“With this patent, Hoth Therapeutics continues to bolster its diverse IP portfolio, which now contains multiple patents related to both oncology treatments and dermatological disorders,” stated, Robb Knie, Chairman and CEO of Hoth Therapeutics.  “We look forward to progressing towards additional breakthroughs throughout our entire biopharmaceutical pipeline in the near future.”


About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.


Forward-Looking Statement

This press release includes forward-looking statements based upon Hoth’s current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth’s business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management’s expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled “Risk Factors” in Hoth’s most recent Annual Report on Form 10-K and Hoth’s other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth’s current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.


Investor Contact:

LR Advisors LLC

Email: [email protected] 
www.hoththerapeutics.com

Phone: (678) 570-6791  


 


 


Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-uspto-grant-of-patent-for-targeted-13-cis-ramba-retinamides-for-development-as-a-novel-cancer-therapeutic-301155861.html


SOURCE Hoth Therapeutics, Inc.

 

https://www.biospace.com/article/releases/hoth-therapeutics-announces-uspto-grant-of-patent-for-targeted-13-cis-ramba-retinamides-for-development-as-a-novel-cancer-therapeutic/

This site uses Akismet to reduce spam. Learn how your comment data is processed.